Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Monolithic Power Systems Inc (MPWR) vs 10X Genomics Inc (TXG) Price & Performance

Monolithic Power Systems IncTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Monolithic Power Systems Inc vs 10X Genomics Inc — how do they compare? Monolithic Power Systems Inc trades at $1,200.1 (market cap $59.88B), while 10X Genomics Inc trades at $67.59 (market cap $8.55B). The key difference: Monolithic Power Systems Inc is far larger — about 7× 10X Genomics Inc's market cap, and Monolithic Power Systems Inc pays a 0.66% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

MPWRTXG
Market Cap
$59.88B$8.55B
Sector
UtilitiesHealth
52-Week High
$1.69K$67.29
52-Week Low
$834.14$11.34
Enterprise Value
$58.49B$8.08B
Dividend Yield
0.66%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Monolithic Power Systems Inc

MPWR trades at $1,218.50, down 0.44% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company reported strong Q2 2026 results with EPS of $6.50 beating expectations of $5.87, driven by AI infrastructure demand. Valuation remains elevated with a P/E of 74.34 and P/S of 18.21, while profitability metrics show robust net income margin of 24.5% and ROE of 21.98%.

The stock faces near-term technical pressure but maintains strong fundamental growth prospects from AI and server demand. Analyst consensus remains overwhelmingly bullish with 88% buy ratings and a $1,860 price target representing 53% upside. Key risks include premium valuation concerns and potential double-ordering in enterprise data segments.

10X Genomics Inc

TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.

The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Monolithic Power Systems Inc

Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.

Read more on MPWR

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG